A review of the pharmacology and clinical efficacy of brivaracetam
Pavel Klein,1 Anyzeila Diaz,2 Teresa Gasalla,3 John Whitesides4 1Mid-Atlantic Epilepsy and Sleep Center, Bethesda, MD, USA; 2Neurology Patient Value Unit, UCB Pharma, Smyrna, GA, USA; 3Neurology Patient Value Unit, UCB Pharma, Monheim am Rhein, Germany; 4Asset Development, UCB Pharma, Raleigh, NC, U...
Guardado en:
Autores principales: | Klein P, Diaz A, Gasalla T, Whitesides J |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0ead5ee8de944984aaae69016908159d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
EFFICACY OF BRIVARACETAM IN PEDIATRIC EPILEPSY: AN UP-TO-DATE
por: Antonio Nicotera
Publicado: (2021) -
Overnight switch from levetiracetam to brivaracetam. Safety and tolerability
por: L. Abraira, et al.
Publicado: (2021) -
Clinical profile of seizure disorder in hospitalized patients in tertiary care center - A prospective cross-sectional study
por: A Alagu Thiyagarajan, et al.
Publicado: (2021) -
Pathogenic in-Frame Variants in SCN8A: Expanding the Genetic Landscape of SCN8A-Associated Disease
por: Jennifer C. Wong, et al.
Publicado: (2021) -
Pharmacokinetic Disposition Difference Between Cyclosporine and Voclosporin Drives Their Distinct Efficacy and Safety Profiles in Clinical Studies
por: Li Y, et al.
Publicado: (2020)